Search company, investor...

Founded Year

2008

Stage

Acquired | Acquired

Valuation

$0000 

About Applikon Biotechnology

Applikon Biotechnology is a privately owned Dutch company developing, manufacturing and supplying bioreactor systems for both research and production use.

Headquarters Location

Heertjeslaan 2

Delft, 2629 JG,

Netherlands

+31(0)10-208 35 55

Loading...

Loading...

Applikon Biotechnology Patents

Applikon Biotechnology has filed 1 patent.

The 3 most popular patent topics include:

  • biochemical engineering
  • biological engineering
  • bioreactors
patents chart

Application Date

Grant Date

Title

Related Topics

Status

8/14/2019

Biotechnology, Bioreactors, Biological engineering, Biochemical engineering, Tissue engineering

Application

Application Date

8/14/2019

Grant Date

Title

Related Topics

Biotechnology, Bioreactors, Biological engineering, Biochemical engineering, Tissue engineering

Status

Application

Latest Applikon Biotechnology News

Cell Expansion Market Size to Worth Around USD 54.48 Bn by 2032

Jun 14, 2023

Key Players Thermo Fisher Scientific, Inc., Corning, Inc., STEMCELL Technologies, Inc., GE Healthcare, Miltenyi Biotec, Becton, Dickinson and Company, Terumo Bct, Inc., Merck KGaA, Sartorius AG, Takara Bio, Inc. and Others Market Dynamics Increasing adoption of regenerative medicines The use of regenerative medicine may be able to replace or repair tissues and even injured organs. The problem concerning cell expansion processes is developed using regeneration strategies. Studying potential cures for illnesses and injuries is beneficial. These conditions could range from fractured bones to neurological illnesses. There is unquestionably an increase in the use of regenerative medicines as we start to comprehend the opportunities that are made possible by applying such a cutting-edge scientific application. This is the lobby for the expanding worldwide market for cell expansion. The method can be applied to a variety of stem cell types, including adult, embryonic, and induced pluripotent cells. Differentiated stem cells can be used safely and successfully to evaluate new medications created by pharmaceutical companies. Moreover, cell-based models for regenerative medicines have the potential to aid researchers in the development of early intervention therapies. The broad applications of the cell expansion technology in health care and science are anticipated to fuel the growth of the global cell expansion market. Restraint Risk contamination during cell expansion Considering the vital function that cell culture plays in biological and medical research, there is enough proof to show that bacteria or other cells regularly infect cell cultures. This impedes scientific research because medications are initially tested on tumour cell lines. Moreover, some inaccurate results are obtained, delaying the start of an appropriate course of treatment. Moreover, it has been noted that cross-contamination might occur while using a pipette more than once while working with several cell cultures. If the infected cells reproduce more quickly than the original cells, they may soon take over the population and change the culture's identity. While the cells from several sources may also be morphologically identical, such events frequently go unnoticed. Chromosome duplications or rearrangements, mutations, and epigenetic alterations can all occur in cells. These factors can hamper the growth of the market. Opportunity Growing investment in regenerative medicine The growing investment in regenerative medicine represents a significant opportunity for the cell expansion market. Cell expansion is a critical component of regenerative medicine, as it involves growing large numbers of cells in vitro for use in various applications, including tissue engineering , gene therapy , and cell-based therapies. As the demand for regenerative medicine continues to grow, the demand for cell expansion technologies and services is also expected to increase. The cell expansion market includes a wide range of products and services, including cell culture media , cell expansion instruments, and contract manufacturing services. The increased investment in regenerative medicine research and development is likely to drive innovation and the development of new cell expansion technologies, including advanced bioreactors and cell sorting technologies. This, in turn, will create opportunities for companies involved in the cell expansion market to develop and commercialize new products and services that meet the needs of the regenerative medicine industry. Challenge Regulatory challenges The cell expansion market involves the production of large numbers of cells for various applications, including research, drug discovery , and cell therapy. As with any industry, the cell expansion market faces regulatory challenges that can present significant obstacles to its growth and development. One major regulatory challenge for the cell expansion market is ensuring that the cells produced meet strict quality and safety standards. This is particularly important for cell therapy applications, where the cells are intended to be used in patients. Regulatory bodies, such as the U.S. Food and Drug Administration (FDA), require that cells produced for therapeutic use meet stringent criteria for purity, potency, and identity. Meeting these standards can be time-consuming and costly, and failure to comply with them can result in delays in product approval or even rejection by regulatory agencies. Another regulatory challenge for the cell expansion market is navigating the complex and evolving regulatory landscape. Recent Developments: In July 2021, an agreement has been reached between Novartis Gene Therapies, a division of Novartis AG, and AGC Biologics, a significant global biopharmaceutical contract development and manufacturing organisation (CDMO), to purchase a state-of-the-art commercial manufacturing facility for cell and gene therapy in Longmont, Colorado, in the United States. Upon completion of a thorough due diligence process, the facility will provide AGC Biologics with much greater capacity and space to continue building its end-to-end Cell and Gene Therapy offering and ensure supply security for both current and potential clients. In March 2020, Sotelab of Brazil, one of Latin America's top suppliers and distributors of laboratory and life sciences equipment, established a partnership with Applikon Biotechnology B.V. (Applikon), a Netherlands business that specializes in upstream bioprocess equipment. The partnership between Applikon and Sotelab Sociedade Técnica de Laboratório Ltda (Sotelab), situated in Rio de Janeiro, significantly boosts the market share of Applikon's sophisticated cultivation systems in South America. Market Segmentation Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/2795 You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 9197 992 333 About Us Precedence Research is a worldwide market research and consulting organization. We give an unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally. For Latest Update Follow Us:

Applikon Biotechnology Frequently Asked Questions (FAQ)

  • When was Applikon Biotechnology founded?

    Applikon Biotechnology was founded in 2008.

  • Where is Applikon Biotechnology's headquarters?

    Applikon Biotechnology's headquarters is located at Heertjeslaan 2, Delft.

  • What is Applikon Biotechnology's latest funding round?

    Applikon Biotechnology's latest funding round is Acquired.

  • Who are the investors of Applikon Biotechnology?

    Investors of Applikon Biotechnology include Getinge.

Loading...

Loading...

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.